Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine Lcells. Although several nutrients induce GLP-1 secretion, there is little evidence to suggest that non-nutritive compounds directly increase GLP-1 secretion. Here, we hypothesized that anthocyanins induce GLP-1 secretion and thereby significantly contribute to the prevention and treatment of diabetes. Delphinidin 3-rutinoside (D3R) was shown to increase GLP-1 secretion in GLUTag L cells. The results suggested that three hydroxyl or two methoxyl moieties on the aromatic ring are essential for the stimulation of GLP-1 secretion. Notably, the rutinose moiety was shown to be a potent enhancer of GLP-1 secretion, but only in conjunction with three hydroxyl moieties on the aromatic ring (D3R). Receptor antagonist studies revealed that D3R-stimulates GLP-1 secretion involving inositol 1,4,5-trisphosphate receptor-mediated intracellular Ca 
Introduction
Glucagon-like peptide-1 (GLP-1) secreted from enteroendocrine L-cells is one type of incretin and stimulates glucose-dependent insulin secretion and proliferation of pancreatic β-cells [1] [2] [3] . Due to its established role in the metabolic response, particularly glucose homeostasis, GLP-1 is an important factor in the treatment and prevention of type 2 diabetes. Several therapeutic approaches to enhance GLP-1 action are being studied and include the use of GLP-1 analogs, which improve glycemic control in type 2 diabetes patients [4, 5] . However, GLP-1 analogs are not suitable for oral administration and must be hypodermically injected. As circulating GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase IV (DPP-4) through cleavage of the N-terminal region of intact GLP-1 [6, 7] , DPP-4 inhibitors are promising therapeutic agents for extending the half-life of endogenously secreted GLP-1. To date, several DPP-4 antagonists have been identified that ameliorate hyperglycemia in type 2 diabetes patients [8, 9] .
These approaches are effective for controlling blood glucose levels in type 2 diabetic patients. However, an alternative therapeutic approach is to increase endogenous GLP-1 secretion through modulation of the secretory mechanisms in intestinal L cells using pharmaceutical agents or dietary factors. This novel therapeutic strategy may help treat diabetes and decrease the required doses of other diabetic medicines. A number of nutrients and small molecules are reported to increase GLP-1 secretion in vitro and in vivo and include certain fatty acids [10] [11] [12] , as well as glutamine and arginine, which are well-characterized GLP-1 secretagogues [13] [14] [15] . Protein hydrolysates have also been reported to induce enhanced GLP-1 secretion [16] [17] [18] [19] .
We previously demonstrated that curcumin, a yellow pigment isolated from turmeric, markedly increases GLP-1 secretion in the murine GLUTag cell line [20] . Despite the abundant evidence that several nutrients and drug candidates stimulate GLP-1 secretion, there is little evidence that non-nutritive food compounds, and not the nutrients themselves, are able to directly enhance GLP-1 secretion.
Anthocyanins are flavonoid phytopigments [21] that are found naturally in plants in the form of glycosides and are widely available in fruits and vegetables commonly consumed by humans. Recent research suggests that the consumption of anthocyanin-rich foods is associated with various health benefits [21] [22] [23] [24] . Our research group demonstrated that anthocyaninrich extract (bilberry and black soybean) reduces blood glucose levels and improves insulin sensitivity in type 2 diabetic mice [25, 26] . A recent epidemiological study showed that a higher consumption of anthocyanins and anthocyanin-rich fruit is associated with a lower risk of type 2 diabetes [24] . The molecular mechanism underlying this effect can be explained by the activation of AMP-activated protein kinase [25, 26] . However, at least six principal types of anthocyanidins have been identified to date (Fig 1) , and many anthocyanins can be derived from these six types through structural modifications, such as the addition of substituent groups on the B ring, conjugation of various types and numbers of sugars, and the presence or absence of an acyl group. For this reason, anthocyanins may have various anti-diabetic effects via mechanisms other than AMP-activated protein kinase activation, such as the modification of GLP-1 activity. We hypothesized that anthocyanins facilitate GLP-1 secretion and thereby contribute to the prevention and treatment of diabetes.
In the present study, we demonstrated that delphinidin 3-rutinoside (D3R) significantly increased GLP-1 secretion in GLUTag cells, and clarified the structure-activity relationship using anthocyanin derivatives. Moreover, this increase was found to involve the inositol 1,4,5-trisphosphate receptor (IP 3 R)-mediated intracellular Ca 2+ mobilization-Ca 2+ /calmodulin-dependent kinase II (CaMKII) pathway.
Materials and Methods

Chemicals
The purity of all administered chemicals was over 98%. Commercially available purified anthocyanins (pelargonidin, Pel; pelargonidin 3-glucoside, P3G; cyanidin, Cy; cyanidin 3-glucoside, C3G; cyanidin 3-rutinoside, C3R; delphinidin, Del; delphinidin 3-glucoside, D3G; D3R; peonidin, Peo; peonidin 3-glucoside, Peo3G; peonidin 3-rutinoside, Peo3R; Petunidin, Pet; petunidin 3-glucoside, Pet3G; malvidin, Mal; malvidin 3-glucoside, Mal3G; and malvidin 3,5-diglucoside, Mal3,5dG) were obtained from Tokiwa Phytochemical (Chiba, Japan) and Extrasynthèse (Genay, France). Malvidin 3-rutinoside (Mal3R, > 96% purity) was isolated and purified from tuber dry powder of black ginger (Kaempferia parviflora L.) using preparative ODS-HPLC. medium was collected and centrifuged at 800 × g for 5 min at 4°C to remove any floating cells. Secreted GLP-1 was assayed using an ELISA specific for GLP-1(7-36 amide) and GLP-1(7-37) (GLP-1 ELISA-kit, Millipore, St. Charles, MS) according to the manufacturer's instructions.
GLUTag cell treatment and western blotting
The medium of cultured GLUTag cells was replaced with serum-free Dulbecco's modified Eagle's medium containing 1% BSA for 3 h. After incubation, the cells were treated with vehicle (0.1% DMSO) or D3R for the indicated time periods and conditions and then lysed [28] . Supernatant aliquots were treated with Laemmli sample buffer for 5 min at 100°C [29] , and the samples (20 μg protein) were separated by SDS-PAGE. After electrophoresis, proteins were transblotted onto nitrocellulose membranes and probed with various primary antibodies for 16 h at 4°C. The proteins were then reacted with horseradish peroxidase-conjugated anti-rabbit antibody, and immunoreactivity was visualized using Pierce Western Blotting Substrate (Thermo Fisher Scientific, Yokohama, Japan). The relative density of the stained proteins was evaluated using Multi Gauge Ver 3.0 Densitograph Software (Fuji Film, Tokyo, Japan).
Measurement of intracellular cAMP levels
Cells were extracted by treatment with 0.1 M HCl to avoid degradation of cAMP, and the cAMP levels of the extract were measured using a cyclic AMP EIA kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's instructions.
Statistical analysis
All data are expressed as the means ± SEM. Differences in the GLP-1 secretion or cytosolic cAMP concentrations of GLUTag cells were compared by the Tukey-Kramer test. In other cases, the data were analyzed by two-way ANOVA. If the interaction effect of two components (D3R and inhibitor) was significant, the Tukey-Kramer test was performed to compare the differences between the groups. For all statistical tests, values without a common letter (a, b, c, d and e) on the bar graphs are significantly different at P values < 0.05.
Results
D3R significantly stimulates GLP-1 secretion from GLUTag cells
We first screened various types of anthocyanins for their ability to stimulate GLP-1 secretion in GLUTag cells. The screening revealed that three anthocyanins, D3R, which contains three B-ring hydroxyl moieties and rutinose, Del (the aglycone of D3R), and Mal, which has two methoxyl moieties on the B-ring, resulted in a significant increase in the secretion of GLP-1 by GLUTag cells (Fig 2A) . Notably, however, the GLP-1 secretion induced by D3R was markedly higher compared with that induced by Del and Mal treatment. In addition, D3R stimulated GLP-1 secretion in a concentration-dependent manner (Fig 2B) . Treatment of GLUTag cells with 10 μM D3R was sufficient to significantly stimulate GLP-1 secretion. However, we administered a final concentration of 100 μM of D3R to obtain clearer measurements of the inhibitory effects in the cell signaling pathway experiments (Fig 2B) . Interestingly, glucosyl anthocyanins (P3G, C3G, D3G, Peo3G, Pet3G, Mal3G, and Mal3,5dG) did not significantly increase GLP-1 secretion (data not shown). Additionally, the other examined aglycones (Pel, Cy, Peo, and Pet) and rutinosyl anthocyanins (C3R, Peo3R, and Mal3R) had no detectable effect on GLP-1 secretion. In addition, we confirmed that rutinose itself did not stimulate GLP-1 secretion (Fig 2A) , and that the treatment of GLUTag cells with up to 100 μM of each tested anthocyanin for 2 h had no cytotoxic effects, as shown by a cell viability >98% based on analysis using an automatic live cell counter system (Countess, Life Technologies, Tokyo, Japan) (data not shown). Based on the results of this initial screening, D3R was selected for further studies of the GLP-1 secretion mechanism.
D3R-induced GLP-1 secretion is regulated by endogenous Ca 2+ mobilization GLP-1 secretion occurs through exocytosis and is regulated by various signaling pathways [30] [31] [32] [33] . In particular, increases in cytosolic Ca 2+ levels via the opening of Ca 2+ channels or mobilization of intracellular Ca 2+ stores leads to GLP-1 secretion [34] . To investigate whether D3R affected intracellular Ca 2+ levels, GLUTag cells were first treated with various Ca 2+ fluorescent indicators (Fura2-AM: excitation at 340/380 nm and emission at 510 nm, Fluo3-AM: excitation at 508 nm and emission at 527 nm, Fluo4-AM: excitation at 495 nm and emission at 518 nm, and CaSiR-1 AM: excitation at 650 nm and emission at 664 nm), and the intracellular fluorescence was monitored during exposure to D3R. However, the modulation of intracellular Ca (Fig 3A) .
To examine the GLP-1 secretion-related Ca 2+ response triggered by D3R in more detail, the effect of various Ca 2+ signaling inhibitors on D3R-stimulated GLP-1 secretion was investigated.
In response to increasing intracellular glucose concentration, the ATP/ADP ratio increases and (Fig 3B) . The release of Ca 2+ from intracellular Ca 2+ stores is enhanced following activation of the ryanodine receptor (RyR) and IP 3 R. Here, GLUTag cells pre-treated with the RyR antagonist dantrolene did not canceled increased GLP-1 secretion after exposure to D3R (Fig 3C) . In contrast, the pre-treatment of cells with the IP 3 receptor antagonist 2-APB to inhibit intracellular Ca 2+ mobilization via the IP 3 receptor significantly reduced D3R-stimulated GLP-1 secretion (Fig 3D) .
Activation of CaMKII is involved in D3R-induced GLP-1 secretion
Ca 2+ is a well-known regulator of exocytosis [35] . One of the main factors involved in Ca drug candidate-stimulated secretion of insulin from β-cells [37, 38] . As we recently demonstrated that CaMKII activation is involved in GLP-1 secretion in GLUTag cells treated with curcumin [20] , we speculated that D3R-stimulated GLP-1 secretion proceeds by a similar mechanism. Therefore, we examined the effect of a CaMKII inhibitor on GLP-1 secretion induced by D3R. Pre-treatment of GLUTag cells with the CaMKII inhibitor KN-93 completely blocked D3R-induced GLP-1 secretion (Fig 4A) . Based on this result, the effect of D3R on the phosphorylation of CaMKII was next examined. In GLUTag cells treated with D3R, phosphorylation of CaMKII protein was significantly induced in a time-dependent manner (Fig 4B) . CaMKII phosphorylation was first detected at 5 min and continued to increase, reaching peak levels by 60 min (Fig 4B) . The D3R-induced phosphorylation of CaMKII protein proceeded in a dose-dependent manner (Fig 4C) . The observed phosphorylation pattern is consistent with the GLP-1 secretion profile of D3R-treated cells.
GPR40/120 is involved in D3R-stimulated GLP-1 secretion, but not other possible signaling pathways
It is known that GLP-1 secretion is stimulated via the activation of G protein-coupled receptors (GPRs) in intestinal L cells [39] . For example, GPR40, GPR119, GPR120, and TGR5 mediate the secretion of GLP-1 enteroendocrine cells [40] [41] [42] [43] . The coupling of GPR40/120 to the Gαq subunit leads to the IP 3 -mediated release of intracellular Ca 2+ [42, 44] , whereas Gαs-coupled GPR119 and TGR5 stimulate GLP-1 secretion via the cAMP/protein kinase A (PKA)-dependent pathway [43, 45] . In addition, recent studies have shown that GLP-1 secretagogues are stimulated by the protein kinase C (PKC) or mitogen-activated or extracellular signal-regulated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) pathways [17, [46] [47] [48] . Here, to identify the mechanism underlying D3R-induced GLP-1 secretion, we investigated the possible involvement of these pathways.
The effect of the GPR40/120 antagonist GW1100 on D3R-stimulated GLP-1 secretion was examined (Fig 5A) . The pre-treatment of GLUTag cells with GW1100 significantly decreased GLP-1 secretion in D3R-treated cells compared to vehicle. In contrast, D3R-induced GLP-1 secretion was not affected by the pre-treatment of cells with NF449, a Gαs subunit-selective antagonist that serves as an indicator of GPR119 and TGR5 inhibition (Fig 5B) . The treatment of GLUTag cells with D3R did not significantly affect intracellular cAMP levels (Fig 5C) , and D3R-stimulated GLP-1 secretion was also not affected by the pre-treatment of cells with a PKA inhibitor (H-89; Fig 5D) . In addition, pre-treatment of GLUTag cells with a PKC inhibitor (Gö6983) or a MEK inhibitor (PD98059) did not affect GLP-1 secretion induced by D3R (S1 Fig). 
Discussion
In the present study, we hypothesized that anthocyanins have multiple biological functions and aid in GLP-1 secretion, and that anthocyanins have an anti-diabetic effect through the The treatment of GLUTag cells with various anthocyanins significantly stimulated GLP-1 secretion. The results suggested that modification of the aromatic ring with at least three hydroxyl or two methoxyl moieties is essential for stimulating GLP-1 secretion. Notably, the rutinose moiety was shown to be a potent enhancer of GLP-1 secretion, but only in conjunction with three hydroxyl moieties on the aromatic ring (D3R), as rutinose alone did not stimulate GLP-1 secretion. Interestingly, Mal3R, which contains two methoxyl groups on the aromatic ring and a rutinose moiety, did not significantly stimulate GLP-1 secretion. To our knowledge, this is the first study to demonstrate that certain anthocyanins enhance GLP-1 secretion.
In general, anthocyanins exhibit low bioavailability [49] . In this study, although 10 μM of D3R significantly stimulate GLP-1 secretion (Fig 2B) , the higher levels of concentrations that were tested are not achievable in blood in vivo. However, it is not necessary for such high concentrations of D3R to be absorbed into the body and directly distributed to target cells, as these concentrations are achievable in the gut lumen, where they can exert a significant impact on enteroendocrine L cells.
To [20] . As shown in Fig 4A, -CaMKII pathway regulates D3R-induced GLP-1 secretion in GLUTag cells. However, the exact exocytosis mechanism of GLP-1 from L cell remains unclear. A recent study indicated that vesicle-associated membrane protein 2 (VAMP2), which is involved in vesicular transport and membrane fusion, has an essential role in GLP-1 exocytosis [30] . Interestingly, binding of CaMKII to syntaxin1a, which interacts with VAMP2, is an important process in the regulation of exocytosis [50] , suggesting that the D3R-mediated stimulation of CaMKII modulates VAMP2-mediated GLP-1 exocytosis.
The present study raises another question regarding the primary molecular target of D3R. GPR agonists have been shown to stimulate GLP-1 secretion in intestinal L cells [40] [41] [42] [43] . Here, the pre-treatment of GLUTag cells with a GPR40/120 antagonist, but not a GPR119 or TGR5-related Gαs subunit antagonist, resulted in a significant decrease of D3R-stimulated GLP-1 secretion, suggesting that GPR40/120-intracellular Ca 2+ mobilization via IP 3 R is involved in this process. Although it is also possible that D3R-stimulated GLP-1 secretion is regulated by the GPR119-or TGR5-related cAMP/PKA, PKCz, or MEK-ERK pathways, our results do not support this conclusion.
Conclusions
We demonstrated that the anthocyanin D3R significantly stimulates GLP-1 secretion in GLUTag cells through increased Ca 2+ -CaMKII pathway activation, which may be mediated by GPR40/120 (Fig 6) . However, the secretion of GLP-1 is independent of the cAMP/PKA, PKC, and MEK-ERK pathways. These findings provide a possible molecular mechanism of GLP-1 secretion in intestinal L-cells mediated by foods or drugs and demonstrate a novel biological function of anthocyanins in regards to GLP-1 secretion.
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